GlassScriptPhysician profile
Barbara A Burk
NPI 1588774210
$1,718.29
in general payments reported to CMS, 2019-2025
29 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $231 · 2023: $525 · 2024: $301 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.81 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $207.22 | 2021-2023 | Padcev, Tukysa |
| Pfizer INC. | $185.01 | 2021-2025 | |
| Janssen Biotech, INC. | $167.63 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Abbvie INC. | $141.14 | 2023-2025 | |
| Celgene Corporation | $122.92 | 2022-2024 | Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $93.68 | 2021-2025 | Enhertu |
| Lilly USA, LLC | $81.06 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $70.15 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.89 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.56 | 2021-2025 | Fruzaqla |
| Merck Sharp & Dohme LLC | $57.84 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $47.27 | 2025 | |
| Daiichi Sankyo INC. | $41.80 | 2023 | Injectafer, Enhertu |
| Glaxosmithkline, LLC. | $41.20 | 2023-2025 | Blenrep, Ojjaara, Jemperli |
| Regeneron Healthcare Solutions, INC. | $39.69 | 2022-2024 | Dupixent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $37.75 | 2022-2024 | |
| Stemline Therapeutics INC. | $28.78 | 2025 | Orserdu |
| Caris Mpi, INC. | $27.20 | 2025 | Mi Cancer Seek |
| Sobi, INC | $23.34 | 2022 | |
| Gilead Sciences, INC. | $21.93 | 2022 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Astellas Pharma US INC | $20.33 | 2023 | |
| Incyte Corporation | $19.86 | 2023 | Monjuvi |
| Myriad Genetic Laboratories, INC. | $18.83 | 2025 | Myrisk |
| Alexion Pharmaceuticals, INC. | $17.50 | 2023 | Ultomiris |
| Dova Pharmaceuticals | $16.93 | 2021 | |
| Coherus Oncology, INC. | $15.19 | 2025 | Loqtorzi |
| Amgen INC. | $14.89 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Burk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.